ClinicalTrials.gg
RecruitingNCT07739966Updated Nov 10, 2026

A Study of DS-3939a in Participants With Solid Tumors

A Phase 1/2 interventional study of DS-3939a and Pembrolizumab in Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer and Metastatic Non-Small Cell Lung Cancer, sponsored by Daiichi Sankyo. Recruiting at 76 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Daiichi Sankyo · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingFirst sites in 13 new countries+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo — 5 open to participants now, 16 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Daiichi Sankyo.

Planned enrollment
10th of 31
400 · median 181
Started
2026
with 1 other
Phase 1/2
5 of 41
2 open now
Primary completion
2030-07
later than 14 of 15 live
Registered
40th of 41
by date

Among the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, this one is the 10th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 14 of the 15 other live ones, and was the 40th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.

Read the detailed description

The study includes 2 independent substudies, which have been defined by treatment combination and participant population as follows:

  1. Substudy 1 will evaluate the safety and efficacy of DS-3939a in combination with immunotherapy with or without chemotherapy (carboplatin or pemetrexed) in participants with locally advanced unresectable or metastatic non-squamous (NSQ) NSCLC in the first-line setting.
  2. Substudy 2 will evaluate the safety and efficacy of DS-3939a in combination with DS-1103a or as a monotherapy in participants with locally advanced unresectable or metastatic NSQ NSCLC who are pretreated.

Each sub study will be conducted in 2 parts: Dose escalation (Part 1) and Dose expansion (Part 2). The allocation of participants in Part 1 will be non-randomized, and in Part 2, it will be randomized for both substudies.

03

Conditions studied

  • Solid Tumor
  • Locally Advanced Non-Small Cell Lung Cancer
  • Metastatic Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign and date the Main Trial form (ICF), prior to the start of any trial-specific procedures.
  2. Adults greater than or equal to (≥)18 years of age at the time the Main Trial ICF is signed (follow local regulatory requirements if the legal age of consent for trial participation is >18 years old).
  3. documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC.
  4. Has a (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days of the first trial intervention.
  5. (ECOG) performance status (PS) of 0 or 1 assessed no more than 14 days prior to initiation of trial interventions.
  6. Has adequate organ function.
  7. Participants must have by investigator assessment according to v1.1.

Additional Inclusion Criteria for Substudy 1:

1. Participants must not have received prior systemic therapy for locally advanced unresectable or NSCLC.

Additional Inclusion Criteria for Substudy 2:

  1. Participants with AGA (excluding EGFR mutation): Participants have been previously treated with targeted therapy for the AGA and platinum-based chemotherapy for the advanced disease setting.
  2. Participants without AGA: Participants have been previously treated with platinum-based chemotherapy and anti-programmed death-1 ()/programmed death-ligand 1 (PD-L1) antibody
  3. Part 2 only: Participants must have received only 1 or 2 prior lines of anticancer therapy for the advanced disease setting.

Exclusion criteria

Exclusion Criteria:

  1. Prior systemic anticancer therapy targeting MUC1 or TA-MUC1.
  2. Prior systemic anticancer therapy with topoisomerase 1 inhibitor or topoisomerase 1 inhibitor-based antibody-drug conjugate (ADCs) (e.g., datopotamab deruxtexan and Sacituzumab govitecan).
  3. Has spinal cord compression or clinically active central nervous system (CNS) .
  4. Has multiple primary .
  5. Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
  6. Has active or uncontrolled (HIV) infection.
  7. Has active or uncontrolled virus (HBV)/ virus (HCV) infection.
  8. Any of the following within the past 6 months: cerebrovascular accident, , or other arterial thromboembolic event.
  9. Current participation in other therapeutic procedures, except for participation in long term survival follow-up (LTSFU) without any investigational treatment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Substudy 1: Part 1: Cohort A: DS-3939a + Pembrolizumab

    Participants will receive intravenous (IV) infusion of DS-3939a, every 3 weeks (Q3W) on Day 1 of each 21-day cycle until the time radiographic disease progression has been documented as assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator or other reason for treatment discontinuation has been met along with pembrolizumab, 200 milligrams (mg), Q3W on Day 1 of each 21-day cycle up to a maximum of 35 cycles or until treatment discontinuation criteria are me.

    Drug: DS-3939a · Drug: Pembrolizumab

  • Experimental
    Substudy 1: Part 1: Cohort B: DS-3939a + Pembrolizumab + Carboplatin

    Participants will receive IV infusion of DS-3939a, Q3W on Day 1 of each 21-day cycle until the time radiographic disease progression has been documented as assessed per RECIST v1.1 by investigator or other reason for treatment discontinuation has been met along with pembrolizumab, 200 mg, Q3W on Day 1 of each 21-day cycle up to a maximum of 35 cycles and carboplatin at area under the curve (AUC) 5, Q3W on Day 1 of each 21-day cycle up to maximum of 4 cycles or until the discontinuation criteria are met.

    Drug: DS-3939a · Drug: Pembrolizumab · Drug: Carboplatin

  • Experimental
    Substudy 1: Part 1: Cohort C: DS-3939a + Pembrolizumab + Pemetrexed

    Participants will receive IV infusion of DS-3939a, Q3W on Day 1 of each 21-day cycle until the time radiographic disease progression has been documented as assessed per RECIST v1.1 by investigator or other reason for treatment discontinuation has been met along with pembrolizumab, 200 mg, Q3W on Day 1 of each 21-day cycle up to a maximum of 35 cycles and pemetrexed 500 milligrams per meter square (mg/m\^2), Q3W on Day 1 of each 21-day cycle until the discontinuation criteria are met.

    Drug: DS-3939a · Drug: Pembrolizumab · Drug: Pemetrexed

  • Experimental
    Substudy 1: Part 2: Cohort A: DS-3939a + Pembrolizumab

    Participants will receive IV infusion of DS-3939a at the recommended dose for expansion (RDE) based on Part 1 data, along with pembrolizumab, 200 mg, Q3W on Day 1 of each 21-day cycle up to a maximum of 35 cycles or until the discontinuation criteria are met.

    Drug: DS-3939a · Drug: Pembrolizumab

  • Experimental
    Substudy 1: Part 2: Cohort B: DS-3939a + Pembrolizumab + Carboplatin

    Participants will receive IV infusion of DS-3939a at the RDE based on Part 1 data, along with pembrolizumab, 200 mg, Q3W on Day 1 of each 21-day cycle up to a maximum of 35 cycles and carboplatin at AUC 5, Q3W on Day 1 of each 21-day cycle up to a maximum of 4 cycles or until the discontinuation criteria are met.

    Drug: DS-3939a · Drug: Pembrolizumab · Drug: Carboplatin

  • Experimental
    Substudy 1: Part 2: Cohort C: DS-3939a + Pembrolizumab + Pemetrexed

    Participants will receive IV infusion of DS-3939a at the RDE based on Part 1 data, along with pembrolizumab, 200 mg, Q3W on Day 1 of each 21-day cycle up to a maximum of 35 cycles and pemetrexed 500 mg/m\^2, Q3W on Day 1 of each 21-day cycle until the discontinuation criteria are met.

    Drug: DS-3939a · Drug: Pembrolizumab · Drug: Pemetrexed

  • Active comparator
    Substudy 1: Part 2: Cohort D: Pembrolizumab + Carboplatin + Pemetrexed

    Participants will receive IV infusions of pembrolizumab, 200 mg, Q3W on Day 1 of each 21-day cycle up to a maximum of 35 cycles, along with carboplatin at AUC 5, Q3W on Day 1 of each 21-day cycle up to maximum of 4 cycles and pemetrexed 500 mg/m\^2, Q3W on Day 1 of each 21-day cycle until the discontinuation criteria are met.

    Drug: Pembrolizumab · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Substudy 2: Part 1: DS-3939a + DS-1103a

    Participants will receive IV infusion of DS-3939a, along with DS-1103a, Q3W on Day 1 of each 21-day cycle until radiographic disease progression as assessed by investigator, or other reason for treatment discontinuation criteria are met.

    Drug: DS-3939a · Drug: DS-1103a

  • Experimental
    Substudy 2: Part 2: DS-3939a + DS-1103a

    Participants will receive IV infusion of DS-3939a at the RDE based on Part 1 data, along with DS-1103a, Q3W on Day 1 of each 21-day cycle until radiographic disease progression as assessed by investigator, or other reason for treatment discontinuation criteria are met.

    Drug: DS-3939a · Drug: DS-1103a

  • Active comparator
    Substudy 2: Part 2: DS-3939a

    Participants will receive IV infusion of DS-3939a at the RDE based on Part 1 data, Q3W on Day 1 of each 21-day cycle until radiographic disease progression as assessed by investigator, or other reason for treatment discontinuation criteria are met.

    Drug: DS-3939a

Interventions

  • DrugDS-3939a

    DS-3939a will be administered as an IV infusion.

  • Pembrolizumab will be administered as an IV infusion.

    Also known as: MK-3475

  • Carboplatin will be administered as an IV infusion.

  • Pemetrexed will be administered as an IV infusion.

  • DrugDS-1103a

    DS-1103a will be administered as an IV infusion.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)

    DLT is defined as any treatment-emergent adverse event (TEAE) not attributable to disease or disease-related processes, environmental factors, unrelated trauma, etc., that occurs during the DLT-evaluation Period (Day 1 to the end of Cycle 1) and is Grade ≥3. Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0.

    Time frame: During first cycle (Cycle length=21 days)

  2. Part 1: Number of Participants With TEAEs

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptoms, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are defined as AEs with start or worsening date during the on-treatment period (from the first dose date of trial intervention to 50 days after the last dose date of trial intervention, unless otherwise specified in the applicable sub-study protocol).

    Time frame: Up to approximately 4 years

  3. Part 2: Objective Response (OR) Per RECIST v1.1 as Assessed by Investigator

    OR is defined as participants with a best overall response (BOR) of confirmed response (CR) or confirmed partial response (PR) as assessed by investigator per RECIST v1.1.

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Part 1: OR Per RECIST v1.1 as Assessed by Investigator

    OR is defined as participants with a BOR of confirmed CR or confirmed PR as assessed by investigator per RECIST v1.1.

    Time frame: Up to approximately 5 years

  2. Part 2: Number of Participants With TEAEs

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptoms, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are defined as AEs with start or worsening date during the on-treatment period (from the first dose date of trial intervention to 50 days after the last dose date of trial intervention, unless otherwise specified in the applicable sub-study protocol).

    Time frame: Up to approximately 5 years

  3. Parts 1 and 2: Duration of Response (DoR)

    DoR is defined as the time (month) from date of initial response (CR or PR) to the earlier date of the first objective documentation of radiographic disease progression or death due to any cause.

    Time frame: Up to approximately 5 years

  4. Parts 1 and 2: Disease Control Rate (DCR)

    Disease control is defined as participants with a BOR of confirmed CR, confirmed PR, or stable disease (SD) per RECIST v1.1. DCR is defined as the percentage of participants with disease control.

    Time frame: Up to approximately 5 years

  5. Parts 1 and 2: Time To Response (TTR)

    TTR is defined as the time (month) from the first dose of any trial intervention(s) to the date of the first documentation of objective response in responders (BOR of confirmed CR or confirmed PR).

    Time frame: Up to approximately 5 years

  6. Parts 1 and 2: Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors

    The best percentage change in SoD is defined as the percentage change in the smallest SoD from all postbaseline tumor assessments, taking as reference the baseline SoD. SoD is the sum of diameters from all measurable target lesions.

    Time frame: Up to approximately 5 years

  7. Parts 1 and 2: Progression-Free Survival (PFS) Per RECIST v1.1 as Assessed by Investigator

    PFS is defined as the time (month) from the first dose of any trial intervention(s) to the earlier date of the first objective documentation of radiographic disease progression as assessed by investigator per RECIST v1.1 or death due to any cause.

    Time frame: Up to approximately 5 years

  8. Parts 1 and 2: Overall Survival (OS)

    OS is defined as the time from the first dose of any trial intervention(s) to death due to any cause.

    Time frame: Up to approximately 5 years

  9. Parts 1 and 2: Maximum Plasma Concentration (Cmax) of Anti-TA-MUC1-ac-DXd, Total Anti-TA-MUC1 Antibody and MAAA-1181a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  10. Parts 1 and 2: Time to Reach Maximum Plasma Concentration (Tmax) of Anti-TA-MUC1-ac-DXd, Total Anti-TA-MUC1 Antibody and MAAA-1181a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  11. Parts 1 and 2: Area Under the Plasma Concentration-time Curve up to the Last Quantifiable Time (AUClast) of Anti-TA-MUC1-ac-DXd, Total Anti-TA-MUC1 Antibody and MAAA-1181a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  12. Parts 1 and 2: Area Under the Concentration-time Curve up to Time Tau (AUCtau) of Anti-TA-MUC1-ac-DXd, Total Anti-TA-MUC1 Antibody and MAAA-1181a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  13. Parts 1 and 2: Trough Concentration (Ctrough) of Anti-TA-MUC1-ac-DXd, Total Anti-TA-MUC1 Antibody and MAAA-1181a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  14. Parts 1 and 2: Percentage of Participants With Positive Anti-Drug Antibody (ADA) Against DS-3939a

    Time frame: Up to approximately 5 years

  15. Substudy 2: AUClast of DS-1103a Dosed in Combination With DS-3939a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  16. Substudy 2: AUCtau of DS-1103a Dosed in Combination With DS-3939a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  17. Substudy 2: Cmax of DS-1103a Dosed in Combination With DS-3939a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  18. Substudy 2: Tmax of DS-1103a Dosed in Combination With DS-3939a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  19. Substudy 2: Ctrough of DS-1103a Dosed in Combination With DS-3939a

    Time frame: Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 5 years (Cycle length=21 days)

  20. Substudy 2: Percentage of Participants With Positive ADA for DS-1103a Dosed in Combination With DS-3939a

    Time frame: Up to approximately 5 years

07

Study locations

3 of 76 sites recruiting
  • Highlands Oncology Group (Hog) - Fayetteville
    Fayetteville, Arkansas 72703-4005, United States
    Recruiting
  • UCLA Health
    Los Angeles, California 90095, United States
    Not yet recruiting
  • Moffitt Cancer Center - Magnolia Campus
    Tampa, Florida 33612, United States
    Not yet recruiting
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Not yet recruiting
  • Lifespan Cancer Institute - Rhode Island Hospital
    Providence, Rhode Island 02903, United States
    Not yet recruiting
  • The University of Texas Md Anderson Cancer Center
    Houston, Texas 77030, United States
    Not yet recruiting
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
    Recruiting
  • Instituto Alexander Fleming
    Buenos Aires, C1426ANZ, Argentina
    Not yet recruiting
  • Instituto Oncologico de Cordoba (Ionc) - Fundacion Richardet Longo
    Córdoba, 5000, Argentina
    Not yet recruiting
  • Sanatorio Parque
    Rosario, S2000, Argentina
    Not yet recruiting
  • Cer San Juan - Centro Polivalente de Asistencia E Investigacion Clinica
    San Juan, J5402DIL, Argentina
    Not yet recruiting
  • Clinica Viedma S.A.
    Viedma, R8500, Argentina
    Not yet recruiting
  • Medizinische Universitat Innsbruck
    Innsbruck, 4302, Austria
    Not yet recruiting
  • Karl Landsteiner Institut Fur Lungenforschung Und Pneumologische Onkologie
    Vienna, 1210, Austria
    Not yet recruiting
  • Universite Libre de Bruxelles (Ulb) - Institut Jules
    Brussels, 1070, Belgium
    Not yet recruiting
  • Jessa Ziekenhuis - Hartcentrum Hasselt
    Sint-Truiden, 3800, Belgium
    Not yet recruiting
  • Fundacao Pio Xii-Hospital de Cancer de Barretos
    Barretos, 14784-400, Brazil
    Not yet recruiting
  • Liga Norte Riograndense Contra O Cancer - Pesquisa Clinica
    Natal, 59040-011, Brazil
    Not yet recruiting
  • Irmandade Da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, 90020-090, Brazil
    Not yet recruiting
  • Hospital Sao Lucas Da Pucrs
    Porto Alegre, 95700-068, Brazil
    Not yet recruiting
  • Obras Sociais Irma Dulce - Centro de Pesquisa Oncologica E Clinica (Cpoc)
    Salvador, 40444-130, Brazil
    Not yet recruiting
  • Hospital Israelita Albert Einstein
    São Paulo, 05503-900, Brazil
    Not yet recruiting
  • Beijing Chest Hospital, Capital Medical University
    Beijing, 101149, China
    Not yet recruiting
  • Jilin Cancer Hospital
    Changchun, 130012, China
    Not yet recruiting
  • Hunan Cancer Hospital
    Changsha, 410013, China
    Not yet recruiting
  • The First Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, 510080, China
    Not yet recruiting
  • The First Affiliated Hospital, Zhejiang University School of Medicine (Zhejiang Provincial First Hos
    Hangzhou, 310006, China
    Not yet recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
    Not yet recruiting
  • Harbin Medical University Cancer Hospital
    Harbin, 150040, China
    Not yet recruiting
  • Tianjin Medical University Cancer Institute and Hospital
    Hexi District, Tianjin, 300060, China
    Not yet recruiting
  • Jiamusi Cancer Hospital
    Jiamusi, 154000, China
    Not yet recruiting
  • Shandong University - Shandong Cancer Hospital
    Jinan, 250117, China
    Not yet recruiting
  • Lin Yi Cancer Hospital
    Linyi, 276000, China
    Not yet recruiting
  • Shanghai East Hospital
    Shanghai, 200120, China
    Not yet recruiting
  • Taizhou Hospital of Zhejiang Province
    Taizhou, 317000, China
    Not yet recruiting
  • Hubei Cancer Hospital
    Wuhan, 430079, China
    Not yet recruiting
  • Henan Provincial Cancer Hospital
    Zhengzhou, 450008, China
    Not yet recruiting
  • Aphm - Hopital Nord
    Marseille, 13005, France
    Not yet recruiting
  • Centre Hospitalier Universitaire de Montpellier (Chu Montpellier) - Hopital Lapeyronie
    Montpellier, 34090, France
    Not yet recruiting
  • Hospitalier Paris Saint-Joseph
    Paris, 75014, France
    Not yet recruiting
  • Centre Hospitalier Universitaire (Chu) de Rennes - Hopital de Pontchaillou
    Rennes, 35000, France
    Not yet recruiting
  • Institut de Cancerologie de L'Ouest (Ico) - Saint-Herblain
    Saint-Herblain, 44800, France
    Not yet recruiting
  • Hopital Foch
    Suresnes, 92150, France
    Not yet recruiting
  • Unicancer-Institut de Cancerologie de Lorraine (Icl)
    Vandœuvre-lès-Nancy, 54500, France
    Not yet recruiting
  • Institut Gustave Roussy
    Villejuif, 94805, France
    Not yet recruiting
  • Istituto Europeo Di Oncologia
    Milan, 20141, Italy
    Not yet recruiting
  • Azienda Ospedaliero - Universitaria San Luigi Gonzaga
    Orbassano, 10043, Italy
    Not yet recruiting
  • Universita Degli Studi Di Pavia-Fondazione Irccs Policlinico San Matteo
    Pavia, 27100, Italy
    Not yet recruiting
  • Azienda Ospedaliera Di Perugia - Ospedale Santa Maria Della Misericordia
    Perugia, 6129, Italy
    Not yet recruiting
  • Servizio Sanitario Regionale Emilia-Romagna - Azienda Unita Sanitaria Locale Della Romagna - Ospedal
    Ravenna, 48121, Italy
    Not yet recruiting
  • Istituti Fisioterapici Ospitalieri (Ifo) - Istituto Nazionale Tumori Regina Elena (Ire)
    Rome, 144, Italy
    Not yet recruiting
  • Fondazione Policlinico Universitario Agostino
    Rome, 168, Italy
    Not yet recruiting
  • Kansai Medical University Hospital
    Hirakata, 573-1191, Japan
    Recruiting
  • National Cancer Center Hospital East
    Kashiwa-shi, 277-8577, Japan
    Not yet recruiting
  • National Hospital Organization (Nho) Shikoku Cancer Center
    Matsuyama, 791-0280, Japan
    Not yet recruiting
  • Sendai Kousei Hospital
    Sendai, 980-0873, Japan
    Not yet recruiting
  • National Hospital Organization Hokkaido Cancer Center
    Shiroishi-ku, Sapporo-shi, 003-0804, Japan
    Not yet recruiting
  • Hospital Del Mar
    Barcelona, 8003, Spain
    Not yet recruiting
  • Hospital Universitario Arnau de Vilanova (Lleida)
    Lleida, 25198, Spain
    Not yet recruiting
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
    Not yet recruiting
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
    Not yet recruiting
  • Hospital Universitario Virgen de La Victoria
    Málaga, 90095, Spain
    Not yet recruiting
  • Hospital Clinico Universitario de Santiago
    Santiago de Compostela, 15705, Spain
    Not yet recruiting
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
    Not yet recruiting
  • Hospital Universitario Virgen Del Rocio (Huvr)
    Seville, 41013, Spain
    Not yet recruiting
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
    Not yet recruiting
  • National Cheng Kung University Hospital Nckuh
    Tainan, 704031, Taiwan
    Not yet recruiting
  • National Taiwan University Hospital
    Taipei, 100021, Taiwan
    Not yet recruiting
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
    Not yet recruiting
  • Ankara Bilkent Sehir Hastanesi (Ankara City Hospital)
    Ankara, 6800, Tunisia
    Not yet recruiting
  • Memorial Ankara Hospital
    Ankara, 6520, Turkey (Türkiye)
    Not yet recruiting
  • Liv Hospital Ankara
    Ankara, 6680, Turkey (Türkiye)
    Not yet recruiting
  • T.C. Saglik Bakanligi Ankara Ataturk Egitim Ve Arastirma Hastanesi (Ankara Ataturk Training and Rese
    Ankara, 6800, Turkey (Türkiye)
    Not yet recruiting
  • Ege Universitesi Tip Fakultesi Hastanesi
    Bornova, 35100, Turkey (Türkiye)
    Not yet recruiting
  • Istanbul Medeniyet University Goztepe Prof. Dr. Suleyman Yalcin City Hospital
    Istanbul, 34722, Turkey (Türkiye)
    Not yet recruiting
  • Adana City Training & Research Hospital
    Yüreğir, 1370, Turkey (Türkiye)
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that have reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2030, 45 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 45 months is below that.

Counting every sponsor, half of 435 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartActual
Oct 13, 2026
Primary completionEst.
Jul 31, 2030
CompletionEst.
Jan 29, 2032
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
76 sites added — first sites in Argentina, Austria, Belgium, Brazil, China and 8 more
All 13 countries

Argentina, Austria, Belgium, Brazil, China, France, Italy, Japan, Spain, Taiwan, Tunisia, Turkey (Türkiye), United States

. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Inova Schar Cancer Institute · Fairfax, United StatesNot yet recruiting→Recruiting
  • Kansai Medical University Hospital · Hirakata, JapanNot yet recruiting→Recruiting
Show 76 added (15 China, 8 France, 8 Spain, 7 United States, 7 Italy, 6 Brazil, 6 Turkey (Türkiye), 5 Argentina, 5 Japan, 4 Taiwan, 2 Austria, 2 Belgium, 1 Tunisia)
  • Highlands Oncology Group (Hog) - Fayetteville · Fayetteville, United States
  • UCLA Health · Los Angeles, United States
  • Moffitt Cancer Center - Magnolia Campus · Tampa, United States
  • Oregon Health & Science University · Portland, United States
  • Lifespan Cancer Institute - Rhode Island Hospital · Providence, United States
  • The University of Texas Md Anderson Cancer Center · Houston, United States
  • Inova Schar Cancer Institute · Fairfax, United States
  • Instituto Alexander Fleming · Buenos Aires, Argentina
  • Instituto Oncologico de Cordoba (Ionc) - Fundacion Richardet Longo · Córdoba, Argentina
  • Sanatorio Parque · Rosario, Argentina
  • Cer San Juan - Centro Polivalente de Asistencia E Investigacion Clinica · San Juan, Argentina
  • Clinica Viedma S.A. · Viedma, Argentina
  • Medizinische Universitat Innsbruck · Innsbruck, Austria
  • Karl Landsteiner Institut Fur Lungenforschung Und Pneumologische Onkologie · Vienna, Austria
  • Universite Libre de Bruxelles (Ulb) - Institut Jules · Brussels, Belgium
  • Jessa Ziekenhuis - Hartcentrum Hasselt · Sint-Truiden, Belgium
  • Fundacao Pio Xii-Hospital de Cancer de Barretos · Barretos, Brazil
  • Liga Norte Riograndense Contra O Cancer - Pesquisa Clinica · Natal, Brazil
  • Irmandade Da Santa Casa de Misericordia de Porto Alegre · Porto Alegre, Brazil
  • Hospital Sao Lucas Da Pucrs · Porto Alegre, Brazil
  • Obras Sociais Irma Dulce - Centro de Pesquisa Oncologica E Clinica (Cpoc) · Salvador, Brazil
  • Hospital Israelita Albert Einstein · São Paulo, Brazil
  • Beijing Chest Hospital, Capital Medical University · Beijing, China
  • Jilin Cancer Hospital · Changchun, China
  • Hunan Cancer Hospital · Changsha, China
  • The First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine (Zhejiang Provincial First Hos · Hangzhou, China
  • Zhejiang Cancer Hospital · Hangzhou, China
  • Harbin Medical University Cancer Hospital · Harbin, China
  • Tianjin Medical University Cancer Institute and Hospital · Hexi District, Tianjin, China
  • …and 46 more on the registry record
across 2 updates, Oct 28, 2026 – Nov 10, 2026
Start date
Oct 1, 2026→Oct 13, 2026 (actual)
Oct 28, 2026
Show all 2 updates
  1. Nov 10, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Inova Schar Cancer Institute · Fairfax, United StatesNot yet recruiting→Recruiting
    • Kansai Medical University Hospital · Hirakata, JapanNot yet recruiting→Recruiting
    + 1 other change: verification date
  2. Oct 28, 2026
    Not yet recruiting→Recruiting
    76 sites added — first sites in Argentina, Austria, Belgium, Brazil, China and 8 more
    All 13 countries

    Argentina, Austria, Belgium, Brazil, China, France, Italy, Japan, Spain, Taiwan, Tunisia, Turkey (Türkiye), United States

    Show 76 added (15 China, 8 France, 8 Spain, 7 United States, 7 Italy, 6 Brazil, 6 Turkey (Türkiye), 5 Argentina, 5 Japan, 4 Taiwan, 2 Austria, 2 Belgium, 1 Tunisia)
    • Highlands Oncology Group (Hog) - Fayetteville · Fayetteville, United States
    • UCLA Health · Los Angeles, United States
    • Moffitt Cancer Center - Magnolia Campus · Tampa, United States
    • Oregon Health & Science University · Portland, United States
    • Lifespan Cancer Institute - Rhode Island Hospital · Providence, United States
    • The University of Texas Md Anderson Cancer Center · Houston, United States
    • Inova Schar Cancer Institute · Fairfax, United States
    • Instituto Alexander Fleming · Buenos Aires, Argentina
    • Instituto Oncologico de Cordoba (Ionc) - Fundacion Richardet Longo · Córdoba, Argentina
    • Sanatorio Parque · Rosario, Argentina
    • Cer San Juan - Centro Polivalente de Asistencia E Investigacion Clinica · San Juan, Argentina
    • Clinica Viedma S.A. · Viedma, Argentina
    • Medizinische Universitat Innsbruck · Innsbruck, Austria
    • Karl Landsteiner Institut Fur Lungenforschung Und Pneumologische Onkologie · Vienna, Austria
    • Universite Libre de Bruxelles (Ulb) - Institut Jules · Brussels, Belgium
    • Jessa Ziekenhuis - Hartcentrum Hasselt · Sint-Truiden, Belgium
    • Fundacao Pio Xii-Hospital de Cancer de Barretos · Barretos, Brazil
    • Liga Norte Riograndense Contra O Cancer - Pesquisa Clinica · Natal, Brazil
    • Irmandade Da Santa Casa de Misericordia de Porto Alegre · Porto Alegre, Brazil
    • Hospital Sao Lucas Da Pucrs · Porto Alegre, Brazil
    • Obras Sociais Irma Dulce - Centro de Pesquisa Oncologica E Clinica (Cpoc) · Salvador, Brazil
    • Hospital Israelita Albert Einstein · São Paulo, Brazil
    • Beijing Chest Hospital, Capital Medical University · Beijing, China
    • Jilin Cancer Hospital · Changchun, China
    • Hunan Cancer Hospital · Changsha, China
    • The First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, China
    • The First Affiliated Hospital, Zhejiang University School of Medicine (Zhejiang Provincial First Hos · Hangzhou, China
    • Zhejiang Cancer Hospital · Hangzhou, China
    • Harbin Medical University Cancer Hospital · Harbin, China
    • Tianjin Medical University Cancer Institute and Hospital · Hexi District, Tianjin, China
    • …and 46 more on the registry record
    Start date Oct 1, 2026→Oct 13, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07739966
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Oct 13, 2026
Primary completion
Jul 31, 2030 (estimated)
Completion
Jan 29, 2032 (estimated)
Last update
Nov 10, 2026

Study contacts

Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
9089926400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion